Correlation analysis of [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy

References

• Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560.
   PubMed Web of Science ®Google Scholar
• Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117.
   PubMed Web of Science ®Google Scholar
• Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–2190.
   PubMed Web of Science ®Google Scholar
• Machtay M, Paulus R, Moughan J, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012;7:716–722.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199.
   PubMed Web of Science ®Google Scholar
• Wanet M, Lee JA, Weynand B, et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother Oncol. 2011;98:117–125.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy [18]Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392.
   PubMed Web of Science ®Google Scholar
• Calais J, Thureau S, Dubray B, et al. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. J Nucl Med. 2015;56:196–203.
   PubMed Web of Science ®Google Scholar
• Berwouts D, Olteanu LA, Duprez F, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol. 2013;107:310–316.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, De Ruysscher D, van der Salm A, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104:67–71.
   PubMed Web of Science ®Google Scholar
• Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113.
   PubMed Web of Science ®Google Scholar
• Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. BJR. 1953;26:638–648.
   PubMed Web of Science ®Google Scholar
• Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921–927.
   PubMed Web of Science ®Google Scholar
• Thorwarth D, Eschmann SM, Paulsen F, et al. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68:291–300.
   PubMed Web of Science ®Google Scholar
• Lohith TG, Kudo T, Demura Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–1953.
   PubMed Web of Science ®Google Scholar
• Bollineni VR, Kerner GS, Pruim J, et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III–IV non-small cell lung cancer patients. J Nucl Med. 2013;54:1175–1180.
   PubMed Web of Science ®Google Scholar
• Zegers CM, van Elmpt W, Reymen B, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res. 2014;20:6389–6397.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, Zegers CM, Reymen B, et al. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging. 2016;43:240–248.
   PubMed Web of Science ®Google Scholar
• Di Perri D, Lee JA, Bol A, et al. Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy. Acta Oncol. 2017;56:516–524.
   PubMed Web of Science ®Google Scholar
• Goossens S, Senny F, Lee JA, et al. Assessment of tumor motion reproducibility with audio-visual coaching through successive 4D CT sessions. J Appl Clin Med Phys. 2014;15:4332.
   PubMed Web of Science ®Google Scholar
• Servagi-Vernat S, Differding S, Hanin FX, et al. A prospective clinical study of 18F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging. 2014;41:1544–1552.
   PubMed Web of Science ®Google Scholar
• Janssens G, Jacques L, Orban de Xivry J, et al. Diffeomorphic registration of images with variable contrast enhancement. Int J Biomed Imaging. 2011;2011:891585.
   PubMedGoogle Scholar
• Wanet M, Sterpin E, Janssens G, et al. Validation of the mid-position strategy for lung tumors in helical TomoTherapy. Radiother Oncol. 2014;110:529–537.
   PubMed Web of Science ®Google Scholar
• Wolthaus JW, Sonke JJ, van Herk M, et al. Reconstruction of a time-averaged midposition CT scan for radiotherapy planning of lung cancer patients using deformable registration. Med Phys. 2008;35:3998–4011.
   PubMed Web of Science ®Google Scholar
• Kruis MF, van de Kamer JB, Houweling AC, et al. PET motion compensation for radiation therapy using a CT-based mid-position motion model: methodology and clinical evaluation. Int J Radiat Oncol Biol Phys. 2013;87:394–400.
   PubMed Web of Science ®Google Scholar
• Thureau S, Chaumet-Riffaud P, Modzelewski R, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′-18F-fluorothymidine PET images in lung cancer. J Nucl Med. 2013;54:1543–1550.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71:1402–1407.
   PubMed Web of Science ®Google Scholar
• Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Fujii H, Hayashi Y, et al. Prognostic significance of hypoxic PET using [18]F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer. Lung Cancer. 2016;91:56–66.
   PubMed Web of Science ®Google Scholar
• Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
   PubMed Web of Science ®Google Scholar
• Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926.
   PubMed Web of Science ®Google Scholar
• Vera P, Bohn P, Edet-Sanson A, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with (1)(8)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)(8)F-fluoro-thymidine (FLT), and hypoxia with (1)(8)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98:109.
   PubMed Web of Science ®Google Scholar
• Sachpekidis C, Thieke C, Askoxylakis V, et al. Combined use of [18]F-FDG and [18]F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging. 2015;5:127–142.
   PubMedGoogle Scholar
• Carlin S, Zhang H, Reese M, et al. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515–521.
   PubMed Web of Science ®Google Scholar
• Zegers CM, van Elmpt W, Wierts R, et al. Hypoxia imaging with [(1)(8)F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol. 2013;109:58–64.
   PubMed Web of Science ®Google Scholar
• Liu C, Pierce LA II, Alessio AM, et al. The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging. Phys Med Biol. 2009;54:7345–7362.
   PubMed Web of Science ®Google Scholar
• Neicu T, Berbeco R, Wolfgang J, et al. Synchronized moving aperture radiation therapy (SMART): improvement of breathing pattern reproducibility using respiratory coaching. Phys Med Biol. 2006;51:617–636.
   PubMed Web of Science ®Google Scholar
• Christian N, Deheneffe S, Bol A, et al. Is [18]F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol. 2010;97:183–188.
   PubMed Web of Science ®Google Scholar
• Ljungkvist AS, Bussink J, Rijken PF, et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002;54:215–228.
   PubMed Web of Science ®Google Scholar
• Trani D, Yaromina A, Dubois L, et al. Preclinical assessment of efficacy of radiation dose painting based on intratumoral FDG-PET uptake. Clin Cancer Res. 2015;21:5511–5518.
   PubMed Web of Science ®Google Scholar